ClinicalTrials.gg
Not yet recruitingNCT07433413AUDUpdated Feb 25, 2026

Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder

A Phase 3 interventional study of Naltrexone and placebo in Alcohol Use Disorder (AUD), sponsored by Shenzhen Sciencare Medical Industries Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Shenzhen Sciencare Medical Industries Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing naltrexone in Alcoholism — 5 open to participants now, 5 under way, 2 of them phase 3. Naltrexone · Alcoholism.

Planned enrollment
14th of 95
240 · median 108
Started
2026
with 1 other
Phase 3
21 of 95
2 open now
Registered
95th of 95
by date

Among the 95 studies testing naltrexone in Alcoholism, this one is the 14th largest by planned enrollment, is one of 2 that started in 2026, is one of 21 in phase 3, and was the 95th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

5 of the 95 studies testing naltrexone in Alcoholism are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing naltrexone in Alcoholism, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial.

The study plans to enroll 240 adult patients with Alcohol Use Disorder (AUD). After providing written informed consent and undergoing screening for eligibility criteria, eligible subjects will be randomized in a 2:1 ratio to receive treatment in either the experimental group (1.5 g Naltrexone Hydrochloride Implant plus non-specific supportive psychotherapy) or the control group (placebo implant plus non-specific supportive psychotherapy).

On Day 1, subjects will receive a single subcutaneous implantation via a small abdominal incision, receiving either the Naltrexone Hydrochloride Implant or the placebo implant. Following implantation, subjects will be hospitalized for at least 2 hours (the investigator may extend this observation period up to 3 days based on the patient's condition). Subjects will change the wound dressing by themselves on postoperative Day 3.

Efficacy and safety assessments will continue through Week 24 post-randomization/dosing, involving a total of 11 visits. Among these, Visit 5 (Week 3) will be conducted via telephone, while all other visits will be performed as outpatient clinic visits.

03

Conditions studied

  • Alcohol Use Disorder (AUD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of moderate to severe Alcohol Use Disorder (AUD) based on the , Fifth Edition (DSM-5) criteria (meeting four or more diagnostic criteria; refer to Appendix 1 for details).

Exclusion criteria

Exclusion Criteria:

Pregnant, breastfeeding, or pregnant with a positive pregnancy test at screening. This includes women of planning to become pregnant during the study.

Note: Women of childbearing potential are defined as those who are biologically capable of becoming pregnant. To be considered not of childbearing potential, a female subject must meet one of the following: 1) Have had a hysterectomy or bilateral oophorectomy; or 2) Be , defined as having no menses for more than 12 consecutive months.

Significant abnormality in liver function (e.g., or ALT > 3 times the ), liver failure (e.g., presence of ascites, jaundice, coagulopathy, hepatorenal syndrome, or hepatic encephalopathy), or liver/gallbladder ultrasound findings that may significantly impact the assessment of the drug's efficacy and safety.

History of severe pancreatitis or severe delirium tremens. Presence of any severe/uncontrolled systemic diseases (e.g., respiratory, cardiovascular, gastrointestinal, neurological, hematological, urogenital, or endocrine disorders) or psychiatric disorders (e.g., Major Depressive Disorder, Schizophrenia, Bipolar Disorder) or other major illnesses, which in the Investigator's judgment could interfere with the provision of , make study participation unsafe, complicate the interpretation of study outcome data, or otherwise affect the achievement of study objectives.

Potential need for hospitalization or surgery during the study period, including scheduled elective surgeries that cannot be postponed.

Diagnosis of a Substance Use Disorder (other than alcohol or tobacco) based on criteria within the past year (prior to randomization/dosing), such as benzodiazepines, amphetamines, opioids, or cocaine.

Use of anti-relapse medication (e.g., Naltrexone) or receipt of systemic psychological support therapy within 30 days prior to randomization/dosing.

Currently receiving treatment for substance use disorders (e.g., opioids, amphetamines, alcohol), or received opioids within 7 days prior to randomization/dosing, or may require opioid treatment during the study; or positive urine drug screen for opioids, cannabis, amphetamines, etc., or positive naloxone challenge test on the day of randomization/dosing.

Suicidal risk based on Investigator's clinical judgment, or history of suicidal or self-mutilating behavior.

Allergy to the investigational product or its (polylactic acid, magnesium stearate) or local anesthetics.

Currently participating in any investigational drug or device study, or has used any investigational drug or device within 30 days prior to randomization/dosing.

Skin infection at the implantation site, systemic skin disease, or keloid scarring that may affect the assessment of the investigational drug's efficacy and safety.

Clinical or laboratory evidence of (HIV) or Syphilis infection.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Subjects in the experimental group will receive the 1.5 g Naltrexone Hydrochloride Implant plus non-specific supportive psychotherapy.

    Drug: Naltrexone

  • Placebo comparator
    Control Group

    Placebo Implant plus non-specific supportive psychotherapy

    Drug: placebo

Interventions

  • Dosage Form: Implant Specification: 150 mg/Tablet Dosage and Administration: Subcutaneous implantation of 10 tablets (1500 mg) Duration of Treatment: Single administration

  • Drugplacebo

    Dosage Form: Implant Specification: 150 mg/Tablet Dosage and Administration: Subcutaneous implantation of 10 tablets (1500 mg) Duration of Treatment: Single administration

06

What researchers measure

Primary outcomes

  1. Proportion of Heavy Drinking Days During the 24-Week Observation Period Post-Randomization/Post-Dosing

    Specifically, this is calculated as the number of heavy drinking days divided by the number of days at risk for heavy drinking, with the aforementioned days counted up to the date of discontinuation of efficacy observation. "Days at risk for heavy drinking" are defined as the number of days a subject is under efficacy observation starting from the date of hospital discharge following implant administration. Drinking rates are assessed based on the Timeline Follow-Back (TLFB) method, utilizing the daily drinking record form (Appendix 11) completed by the subject and their family members. Heavy drinking is defined as consumption of ≥5 standard drinks per day for males and ≥4 standard drinks per day for females.

    Time frame: 24-Week

Secondary outcomes

  1. Reduction of ≥2 levels in WHO alcohol risk grading

    Specifically, this refers to the change from the baseline WHO alcohol risk level to the level assessed during weeks 21-24. The baseline WHO alcohol risk level is calculated based on TLFB alcohol consumption data collected during the 2-week period prior to detoxification. The WHO alcohol risk level assessed at weeks 21-24 post-randomization/post-dosing is calculated based on the daily drinking record form completed by the subject and their family members.

    Time frame: 24-week

  2. Alcohol Consumption (Total Amount Consumed Over 24 Weeks)

    Calculated based on the daily drinking record form (completed by the subject and their family members) using the Timeline Follow-Back (TLFB) method.

    Time frame: 24-week

  3. Percentage of Days Abstinent (PDA)

    Specifically, this is calculated as the number of days with no alcohol consumption divided by the number of days at risk. The aforementioned days are counted up to the date of discontinuation of efficacy observation. "Days at risk" are defined as the number of days a subject is under efficacy observation, starting from the date of hospital discharge following implant administration. This metric is calculated based on the drinking record form using the Timeline Follow-Back (TLFB) method. Alcohol consumption is defined as any recorded drinking behavior, regardless of the amount or frequency consumed.

    Time frame: 24-week

  4. Longest Continuous Abstinence Duration

    Specifically, this refers to the longest consecutive number of days without alcohol consumption from the time of randomization/dosing until loss to follow-up or study completion. This metric is calculated based on the daily drinking record form (completed by the subject and their family members) using the Timeline Follow-Back (TLFB) method.

    Time frame: 24-week

  5. Proportion of Participants Without Heavy Drinking During the Study Observation Period

    Specifically, this refers to the proportion of subjects who did not engage in heavy drinking from randomization/dosing until loss to follow-up or study completion. This metric is calculated based on the daily drinking record form (completed by the subject and their family members) using the Timeline Follow-Back (TLFB) method.

    Time frame: 24-week

  6. Alcohol Craving Score

    Craving scores are assessed at 1, 2, 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing using a Visual Analog Scale (VAS). VAS Assessment: The VAS consists of a horizontal line. The left end is marked as "0," indicating "No craving," and the right end is marked as "10," indicating "Extreme craving." The intermediate sections represent varying degrees of craving. Subjects are asked to self-evaluate and select a numerical value between 0 and 10 that best represents their current level of craving. A higher numerical value indicates a higher degree of craving.

    Time frame: 24-week

  7. Personal and Social Functioning

    Assessment of personal and social functioning at 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing using the Personal and Social Performance scale (PSP). PSP Total Score Rating Guidelines 71-100: These ratings reflect mild difficulties. 31-70: These ratings reflect various degrees of functional impairment. 0-30: These ratings reflect functional disability, indicating that the patient requires active support or close supervision

    Time frame: 24-week

  8. Pleasure Scale Score (Snaith-Hamilton Pleasure Scale, SHAPS)

    Assessment of the level of agreement regarding pleasure responses in various enjoyable situations at 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing. This is evaluated using the Snaith-Hamilton Pleasure Scale (SHAPS).

    Time frame: 24-week

  9. Family APGAR Questionnaire

    A qualitative assessment of family members' satisfaction regarding five basic family functions at 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing. This assessment is conducted using the Family APGAR Questionnaire.

    Time frame: 24-week

  10. Breath Alcohol Concentration (BrAC)

    Measurement of breath alcohol concentration at 1, 2, 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing using a digital breath alcohol tester.

    Time frame: 24-week

  11. Proportion of Participants Requiring Hospitalization for Detoxification

    Specifically, this refers to the proportion of subjects who required hospitalization for alcohol detoxification following randomization/dosing.

    Time frame: 24-week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Apr 2027, 12 months later.

Of 25 phase 3 interventional studies under Alcoholism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2026
First posted
Feb 25, 2026
StartEst.
Mar 15, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
May 1, 2027
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07433413
Lead sponsor
Shenzhen Sciencare Medical Industries Co., Ltd.
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Mar 15, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Feb 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion